CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The BR31 study: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer is closed to further registrations and Randomization will continue for registered patients for an additional six months. The ALC4 study: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults, has closed to accrual after the completion of target accrual.
The CCTG BR36 trial: A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer, has been centrally activated.
The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: Pharmacist Representatives on Disease Site Committees
Erwin Wanderer is the CCTG Patient Representative on the Genito-Urinary Disease Site Committee and Executive Committees, he resides in Halifax, Nova Scotia and has been CCTG Patient Representative since 2015. Erwin says, "I believe that being involved in a clinical trial can sometimes give patients access to procedures and treatments that they may not have been part of their original options.
CCTG IND232 (NCT02788773) - A Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer has been closed to accrual after the completion of target accrual.
The use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials
Dr. McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology. He currently works as a radiation oncologist at BC Cancer Vancouver. He also is the co-chair of the CCTG Supportive Care Committee. In this video, McKenzie addresses the wide variety of trials the Supportive Care Committee is involved with, as well as potential avenues for new trials that may extend beyond the jurisdiction of cancer research.
This past weekend at the European Society for Medical Oncology congress in Barcelona, Spain, there were many poster presentations by CCTG researchers.
Poster Discussion: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC
